Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Indoles
  • Kidney Neoplasms
  • Patient Preference
  • Pyrimidines
  • Pyrroles
  • Sulfonamides

abstract

  • This innovative cross-over trial demonstrated a significant patient preference for pazopanib over sunitinib, with HRQoL and safety as key influencing factors.

publication date

  • May 10, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2013.50.8267

PubMed ID

  • 24687826

Additional Document Info

start page

  • 1412

end page

  • 8

volume

  • 32

number

  • 14